Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TriLink to Open New Early Phase Therapeutic Manufacturing Facility

Published: Tuesday, May 27, 2014
Last Updated: Tuesday, May 27, 2014
Bookmark and Share
Company's new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014.

TriLink BioTechnologies’ new facility will feature validated ISO Class 7 and ISO Class 8 clean rooms, specifically designed to facilitate fast turnaround of IND-enabling tox and Phase 0/I GMP material. 

TriLink decided to build the facility to meet the growing demand for therapeutic grade GMP mRNA. However, the new facility is fully equipped to manufacture all TriLink products including long RNA, aptamers, oligonucleotides, small molecules and nucleoside triphosphates. Because TriLink’s GMP quality system is specifically designed for early phase materials the service will also be a more economical choice for customers investigating safety and efficacy.

“Building a GMP facility was a natural expansion of our business and leveraged our well-established quality system. TriLink has been at the forefront of the rapidly emerging mRNA market. It was through customer’s inquiries we learned of the need for a supplier of therapeutic grade mRNA and the rest just fell into place,” said Terry Beck, Sr. Vice President.                   

"Our existing quality system, agile business model and extensive nucleic acid synthesis experience place us in a prime position to provide affordable IND and Phase I materials fast," said CEO, Richard Hogrefe, Ph.D. "We hope this new service provides an avenue for more nucleic acid based drugs to make it to the clinic."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TriLink Announces New License Agreement with Biofortuna
Agreement for use of CleanAmp™ dNTPs in Biofortuna’s freeze-drying contract development and production service.
Friday, November 08, 2013
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.
Thursday, May 16, 2013
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
TriLink BioTechnologies Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.
Thursday, May 09, 2013
TriLink BioTechnologies, Inc. Awarded European Patent
TriLink BioTechnologies, Inc. announces the award of their CleanAmp™ Primer patent by the European Patent Office (EPO Patent no. 2032714).
Tuesday, May 31, 2011
TriLink BioTechnologies, Inc. Announces License Agreement with Biofortuna Ltd
TriLink BioTechnologies, announced that it has signed a licensing agreement with Biofortuna Ltd. for use of CleanAmp™ dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits.
Tuesday, September 14, 2010
TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity
The National Institutes of Health recently awarded TriLink BioTechnologies, Inc. (TriLink) a Phase II SBIR Grant of approximately $725,000 to continue their work on developing reagents to enhance the specificity of DNA ligase.
Tuesday, June 22, 2010
TriLink BioTechnologies, Inc. Announces Supply Agreement with ETS Laboratories
TriLink BioTechnologies, Inc. (TriLink) announced that it has signed an agreement with ETS Laboratories (ETS) to supply CleanAmp™ dNTPs for use in their Scorpions™ Wine Spoilage Detection System.
Tuesday, April 27, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Genetic Test Could Improve Blood Cancer Treatment
Testing for genetic risk factors could improve treatment for myeloma – a cancer of the blood and bone marrow – by helping doctors identify patients at risk of developing more aggressive disease.
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!